Council clears EU pharma overhaul, leaving Parliament to test access-for-incentives deal

EU ministers adopted the bloc’s pharmaceutical package on 28 September, moving a major health-market reform closer to the statute book while leaving the final political decision to the European Parliament.¹

The Council compromise sets an eight-year data-protection period for new medicines, adds one year of market protection, creates possible extensions for certain innovative or unmet-need products, and caps combined protection at 11 years — or 12 years where a transferable antibiotic voucher is used.¹⁴ It also gives member states new powers to require sufficient supply of protected medicines, expands the Bolar exemption to prepare generic and biosimilar entry, and introduces a capped incentive for priority antibiotics.¹³

The package seeks to reconcile two objectives that have often pulled EU pharmaceutical policy in opposite directions: improving patient access and resilience against shortages, while keeping Europe attractive for drug development and investment. The Council said the rules are designed to support access to safe, effective and affordable medicines, reduce regulatory burdens, and strengthen security of supply.¹ News coverage framed the same trade-off as an access boost likely to keep pressure on relations with industry over exclusivity and launch obligations.²

Protection deal preserves a long shield, but with conditions

At the centre of the compromise is a new protection timetable. Companies placing a new medicine on the EU market would receive eight years of data protection, during which competitors cannot rely on the originator’s pre-clinical and clinical trial data to support their own applications.¹ They would also receive one year of market protection, limiting immediate competition from generic medicines or biosimilars.¹

Additional protection may be available where medicines meet specified innovation tests, such as comparative clinical trials, trials in more than one member state, or early application in the EU. A further year may be granted for products addressing an unmet medical need. The overall cap is 11 years, with the possibility of 12 years if a transferable exclusivity voucher is used.¹⁴

That structure is the core political bargain. For industry, the Council maintained a substantial baseline data shield and preserved routes to longer protection. For governments and payers, the package narrows the focus to medicines that deliver defined public-health value and sets a ceiling on how long competition can be delayed.³⁵

Supply powers shift leverage toward member states

The Council text gives EU countries authority to require companies benefiting from regulatory protection to supply medicines in sufficient quantities to meet patient needs.¹ The measure responds to a longstanding access problem: EU authorisation does not guarantee that a medicine is launched or available in every national market, where pricing, reimbursement and commercial calculations can differ.³

The Council included safeguards aimed at preventing the supply obligation from being used mainly to support parallel trade — the export of cheaper medicines from one member state for resale in another.¹ That caveat is important to the balance ministers sought. It gives governments a stronger tool against gaps in availability, but signals to companies that the power is meant to address patient access rather than arbitrage between national price systems.

Shortage and availability duties are also part of a wider shift toward supply security. Sector reporting noted that the reforms include faster shortage notifications, prevention planning and monitoring of critical medicines, alongside the member-state power to require supply of certain protected products.⁵

Generic entry and antibiotic incentives

The package expands the Bolar exemption, allowing generic and biosimilar manufacturers to carry out studies, trials and other preparatory steps before the originator’s intellectual-property rights expire.¹ The Council said the scope includes applications for procurement tenders, a change intended to let cheaper alternatives enter on “day one” after protection ends rather than waiting for administrative procedures to start only after expiry.¹²

For antimicrobial resistance, the package introduces a transferable exclusivity voucher for companies that develop priority antibiotics. The voucher gives one additional year of market protection for a product of the company’s choice.¹ To limit the cost for health systems, it cannot be applied to products with annual gross sales above €490 million in the preceding four years.¹³

The voucher is another example of the Council’s calibrated approach: a potentially valuable reward in an area where commercial returns are often weak, constrained by a “blockbuster” limit designed to protect national healthcare budgets.³

Parliament still holds the final step

The reform is not yet in force. The regulation and directive that make up the package still need to be adopted by the European Parliament and published in the EU’s Official Journal before they apply.¹⁶ Fieldfisher noted that the texts reflect the final content of the reform after Council positions and legal-linguistic review, but that formal steps and Official Journal publication remain outstanding.⁶

That makes the Parliament vote the remaining institutional test. MEPs must decide whether to accept the Council’s balance on access obligations, supply-security powers, exclusivity periods, generic readiness and antibiotic incentives. The key question is not whether the package has political momentum — it now clearly does — but whether final adoption proceeds without reopening the compromise between patient access and industry competitiveness.

If adopted, the package would become one of the most significant rewrites of EU medicines law in two decades, changing how medicines are protected from competition, how quickly generics can prepare for entry, and how far governments can go to demand supply in the name of patient need.⁵